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ABSTRACT 
Background: Polycystic ovary syndrome (PCOS) is one of the most common endocrine system disorder affecting women of reproductive age. 
As there are a few studies with inconsistent data available in the literature regarding the prescription pattern and compliance of drugs in 
patients with PCOS, both within and outside India, the present study was undertaken to generate some valid and useful data re garding these 
parameters. 
Objective: Evaluation of drug utilization and assessment of prescribing patterns and patient compliance among Kashmiri women with 
polycystic ovary syndrome. 
Materials and Methods: This study was a prospective, observational and cross-sectional study, which was carried out on Kashmiri females 
diagnosed with PCOS as per Rotterdam criteria of 2003. Patients attending Srinagar based hospitals and clinics over a period of nine months 
were enrolled in the study. Information was collected through personal interviews using a pre-validated, self-administered data collection tool. 
The prescribing patterns of drugs were evaluated by comparison with Endocrine Society Clinical Practice Guidelines. Patient compliance with 
prescribed medicines was assessed using modified Morisky 8-Item Medication Adherence Questionnaire. 
Results: Drugs prescribed to the study patients included oral contraceptive pills (OCPs) 57(46.34%), insulin sensitizers 75 (60.97%), anti-
androgen 37 (30.08%), anti-estrogens 1 (0.81%), progestins 10 (8.13%), dopaminergic agonists 7 (5.69%), steroids 2 (1.62%) and statins 
1(0.81%). 50 (40.65%) patients were highly adherent to their prescribed medications. Conclusion: The study revealed that nature of drugs 
prescribed to the study population was in consonance with the established standard guidelines. Most of the women were highly adherent to 
their prescribed medications. 
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INTRODUCTION 
Polycystic ovary syndrome (PCOS) is one of the most 
common endocrinological disorder, affecting 5–10% of 
women of reproductive age1. It is marked by chronic 
anovulation, hyperandrogenism and/or polycystic ovarian 
morphology2. There is a spectacular increase in the 
prevalence of PCOS all over the world especially in Asia. 
Prevalence of PCOS differs depending upon the criteria used. 
Prevalence of PCOS in Indian adolescents and young girls in 
2014 was about 22.5% by Rotterdam and 10.7% by 
Androgen Excess Society criteria3. 
Drug prescribing is frequently the finished end result of 
most medical consultations4,5. Since great quality 
prescriptions are essential for the accurate dispensing of 
medicines and contribute to minimizing medication errors, 
doctors ought to adhere to the guidelines of prescription 
writing for the advantage of the patient. Prescription pattern 
in PCOS patients has not been studied widely and it needs to 
be evaluated. Since PCOS is the heterogeneous condition of 
varied etiology, the therapeutic options may also differ 
widely, and therefore need to be individualized to address 
the predominant manifestations and defined therapeutic 
objectives. There is paucity in published literature with 
regard to the prescription pattern of PCOS all over the world 
including India. A few studies have been conducted on the 
incidence, prevalence, etiology, epidemiology and 
biochemical profile of PCOS among Kashmiri population, but 
no study has been published regarding evaluation of drug 
utilization among these patients.  
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MATERIALS AND METHODS 
This prospective, observational and cross-sectional study 
was carried over a period of nine months from Srinagar 
based hospitals and clinics from September, 2014 to May, 
2015. 
Patients diagnosed with PCOS as per Rotterdam criteria 
2003 were enrolled in the study. 123 patients of all age 
groups were included and all patients who did not receive 
any drugs were excluded from the study. Patients with PCOS 
as per Rotterdam criteria 2003 attending departments of 
endocrinology/gynaecology/dermatology of Srinagar based 
hospitals and private clinics and those attending health 
camps organized at the University of Kashmir were 
recruited in the study. 
Data collection 
Informed consent was obtained from all the study subjects. 
All the patients included in the study had PCOS as per 
Rotterdam criteria 20036 (Rotterdam, 2003). Study and 
patient specific data was collected from medication charts 
and prescriptions. Consonance of clinical practice, vis-à-vis 
pharmaco-therapeutic management of PCOS, with 
established guidelines among the study patients using pre-
fixed criteria in accordance with published literature was 
evaluated. Data was collected, analyzed and evaluated for 
evolving an overall picture about the drug utilization 
practices among the study subjects. Prescription patterns in 
the study patients were evaluated by collecting details of the 
drug therapies prescribed i.e., the therapeutic class of drugs 
used, dose, route, frequency and duration of therapy. 
Information was collected through personal interviews 
using a pre-validated, structured data collection form. Pre-
validation of the data collection form was done on a group of 
doctors dealing with PCOS patients, incorporating their 
suggestions for improving the clarity, comprehensibility, un-
ambiguity and relevance of the questions asked in the data 
collection form. Patient compliance with prescribed 
medicines was assessed using modified Morisky 8-Item 
Medication Adherence Questionnaire7. The questionnaire 
consists of a set of eight questions having a ‘Yes or No 
answer’. Each question answered in affirmative was given a 
score of 1 and the question answered in negative was given a 
score of 0 and the overall score was calculated. The overall 
score of ‘0’ indicated high adherence,‘1 or 2’ indicated 
medium adherence and a score ‘˃2’ indicated low adherence. 
Reasons for non-adherence to prescribed medications was 
identified from the patient interviews upon counseling and 
accordingly documented. The drug related problems, 
patients response to the treatment and therapeutic outcome 
of the study patients were evaluated through their personal 
interviews using structured data collection form. 
Feedback was obtained from the practicising physicians 
regarding their prescribing preferences for PCOS patients 
using a structured and pre-validated questionnaire. This 
helped in the assessment of their knowledge, attitude and 
practices in care of PCOS. Further the prescribing practices 
of the practicising physicians and their adherence to the 
prescribed guidelines were evaluated by comparing with 
Endocrine Society Clinical Practice Guidelines 20138 and it 
was ascertained whether prescribing in PCOS patients was 
as per the established guidelines or not. 
Statistical Analysis 
Statistical Analysis of the data was carried out using 
GRAPHPAD INSTAT (version 3.1) and SPSS (version 16) 
software. The results were depicted in the form of 
percentages. Significance of the differences observed among 
various variables and outcome measures was ascertained by 
calculating p-values using chi-square test. P values < 0.001 
were deemed to be highly significant. 
RESULTS 
Out of 123 in the study, 31 (25%) patients were married and 
92 (74.97%) patients were unmarried. The mean age of the 
study patients was 23.70 ± 0.41 years and the mean age at 
menarche was 13.06±0.15 years. Prescription pattern of 
study patients revealed that 57(46.34%) had OCPs 
prescribed, 75(60.97%) insulin sensitizers, 37(30.08%) anti-
androgen, 1(0.81%) anti-estrogen, 10(8.13%) progestins, 
7(5.69%) dopamine agonist, 2(1.62%) steroids, 2 (1.62%) 
steroids and 1(0.81%) had statins prescribed as shown in 
Fig 1. Among OCPs prescribed in married population 6(10%) 
were prescribed with E.E +Drospirenone, 2(3.5%) 
E.E+Cyproterone acetate, 2(3.5%) E.E+Norgestal and 0(0%) 
with E.E+Desogestral and in unmarried population 
23(40.3%) were prescribed E.E+Drospirenone, 09(15.7%) 
E.E+Cyproterone acetate, 12(21%) E.E+Norgestal and 
03(5.2%)  E.E+Desogestral with P value of >0.001 as shown 
in Fig 2. 
 
Fig 1: Drug therapy prescribed to the Study patients: 
 
Fig 2: Choice of oral contraceptives prescribed to the 
study patients 
Among insulin sensitizers, 16(21.3%) were prescribed 
metformin, 3(4%) pioglitazone, 5(6.6%) myo-inositol and 
1(1.3%) metformin+myo-inositol in married population. 
Among unmarried population, 40(53.3%) were prescribed 
metformin, 4(5.3%) pioglitazone, 3(4%) myo-inositol, 
2(2.6%) metformin+myo-inositol and 1(1.3%) metformin+ 
sitagliptin with the P value of >0.001 as shown in Fig 3. 
Adherence of the patients towards their medication was 
calculated using Morisky score. It was found out that 50 
(40.65%) of the patients were highly adherent to their 
medication, 41(33.33%) patients had medium adherence 
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and 32 (26.01%) patients were poorly adherent to their 
medication as shown in Table-1. Reasons given by patients 
upon counseling for non-adherence to prescribed 
medication revealed that 65.5% patients' had drug 
intolerance, (18.75%) had lack of information and 
awareness, and 15.62% patients gave non-affordability as 
the reason. 
 
Figure- 3: Choice of insulin sensitizers prescribed to the 
study patients 
In the present study drug related problems were mostly 
seen with metformin 67%, followed by spironolactone 8.9% 
and others. Out of 123 patients with PCOS, 100 (81.3%) 
patients were satisfied with the prescribed drug therapy, 
whereas 23 (18.69%) patients were not satisfied with the 
prescribed drug therapy. Further Therapeutic outcome of 
the patients revealed that 91(73.98%) patients had regular 
menstrual cycles after drug treatment,49 (39.83%) patients 
showed decrease in hirsutism, 11 (8.9%) showed decrease 
in Alopecia,38 (30.89%) showed decrease in 
weight,20(16.26%)showed decrease in Acne, were as15 
(12.19%) had irregular cycles even after drug treatment, 
followed by 6 (4.8%) patients which had no change in 
hirsutism,1(0.8%) had no change in alopecia, 2 (1.62%) had 
no change in weight and 1(0.8%) had no change in acne after 
drug treatment. 
The Comparison of actual prescribing practices and feedback 
obtained from physicians with Endocrine Society Clinical 
Practice (EDCPG) Guidelines of 2013 was done and is shown 
in Table 2. 
Table- 1: Patient compliance to prescribed medications: 
MORRISKY SCORE NO. OF PATIENTS 
0 50(40.65%) 
1 16(13%) 
2 25(20.32%) 
>2 32(26.01%) 
TOTAL(N) 123 
Scores: >2 = low adherence, 1 or 2 = medium adherence, 
0 = high adherence
 
Table-2: Comparison of actual prescribing practices and feedback obtained from physicians with Endocrine Society 
Clinical Practice (EDCPG) Guidelines of 2013. 
Recommendations of Endocrine Society Clinical Practice 
Guideline (ESCPG) 2015  
No. of patients in whom 
prescribing was found in 
accordance with given 
recommendations  
No. of physicians 
whose feedback was 
in consonance with 
ESCPG guidelines 
Hormonal Contraceptives (i.e., oral contraceptives, patches or 
vaginal rings) as first-line management for the menstrual 
abnormalities and hirsutism/acne of PCOS. 
Prescribed as first line 
treatment in 55(44.7%) 
patients and as second line 
treatment in 5(4%) patients  
20 (80%)  
Use of exercise therapy in the management of overweight and 
obesity in PCOS. Weight loss strategies should begin with calorie-
restricted diets (with no evidence that any one type of diet is 
superior) for adolescents and women with PCOS who are 
overweight or obese. 
120(97%) patients were 
advised exercise therapy 
10 (40%)  
Recommendation against the use of Metformin as a first line 
treatment for cutaneous manifestations, for prevention of 
pregnancy complications, or for the treatment of obesity.  
22(18%) patients were 
prescribed Metformin as the 
first line treatment. 
7 (28%)  
Recommend Metformin in women with PCOS who have T2DM or 
IGT who fail upon lifestyle modifications. For women with PCOS 
with menstrual irregularity who cannot take or do not tolerate 
HCs, suggest Metformin as second-line therapy.  
 14(11%) patients were 
prescribed Metformin as the 2nd 
line treatment 
23(92%)  
Recommend Clomiphene citrate (or comparable estrogen 
modulators such as Letrozole) as the first-line treatment of 
anovulatory infertility in women with PCOS. 
1(20%) patient was prescribed 
CC as a 1st line treatment in 
Anovulatory infertility 
3(12%)  
Suggest the use of Metformin as an adjuvant therapy for infertility 
to prevent ovarian hyperstimulation syndrome (OHSS) in women 
with PCOS undergoing in-vitro fertilization (IVF). 
No patient in whom Metformin 
was used as an adjuvant 
therapy for infertility to prevent 
OHSS was detected. 
15(60%)  
Recommend against the use of insulin sensitizers, such as inositols 
(due to lack of benefit) or thiazolidinediones (due to safety 
concerns), for the treatment of PCOS.  
Myo-inositol was prescribed in 
8(6.5%) patients and thiazoli 
dinediones (Pioglitazone) in 
7(5.6%) patients, in contrast to 
the guidelines. 
- 
Suggest against the use of statins for treatment of 
hyperandrogenism and anovulation in PCOS until additional 
studies demonstrate a favorable risk-benefit ratio. 
1(0.81%) such patient was 
prescribed with statins. 
- 
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DISCUSSION 
Present study showed that 43.90% patients with PCOS were 
in the age-group of 19-24years and 39.83% patients in the 
age group of 25-30 years, indicating that PCOS is more 
common among the women between age groups of 19-30 
years. The mean age of study patients was 23.707±0.41 
years and mean age at menarche was 13.065±0.1495 years. 
Most of the previous studies focused upon the similar age 
groups. Nasr et al in 2004 conducted a study on 
oligomenorrheic infertile women, &included patients 
between age group of 21-35 years9.  
The Endocrine Society Clinical Practice Guidelines for PCOS 
recommend Hormonal contraceptives (i.e, oral 
contraceptives, patches, or vaginal rings) as first-line 
management for the menstrual abnormalities and 
hirsutism/acne of PCOS. In the present study oral 
contraceptives, were prescribed as the 1st line treatment in 
55 (44.7%) patients and in 5(4%) patients as 2nd line 
treatment. Further in the study out of 123 patients only 
57(46.34%) patients had OCPs prescribed for PCOS 
indicating that OCPs were not always first line treatment for 
most of the patients. Badawy and Elnashar in 2011, also 
reported oral contraceptive pills (OCPs) as first-line 
treatment for pharmacologic management of hirsutism in 
premenopausal women10. Further 20 (80%) practitioners 
were of the opinion that they prescribe OCPs, as the first line 
treatment for menstrual disturbance and hirsutism which is 
in accordance with the guidelines. 
In the present study 22(18%) patients were prescribed 
Metformin as the first line treatment and 14(11%) patients 
as the second line treatment but Endocrine Society Clinical 
Practice Guideline for PCOS make recommendation against 
the use of Metformin as first line treatment for cutaneous 
manifestations, for prevention of pregnancy complications, 
or for the treatment of obesity. Guidelines recommend use of 
Metformin in women with PCOS who have T2DM or IGT and 
who fail upon lifestyle modifications. Guidelines further 
recommend Metformin as second-line therapy for women 
with PCOS along with menstrual irregularity who cannot 
take or do not tolerate hormonal contraceptives . However 
in the present study oral contraceptives were well tolerated 
as compared to Metformin which was not tolerated well in 
62.5 % patients. Further, only 7(28%) practioners were of 
the opinion that they prescribe Metformin as the first line 
treatment, whereas 23 (92%) practitioners preferred it as 
2nd line treatment for PCOS. Thus most of the practitioners 
prescribed Metformin in accordance with these guidelines. 
Study showed that, 9.33% patients were prescribed 
Pioglitazone and 10.66% were prescribed Myo-inositol 
which is in contrast to the guidelines that recommend 
against the use of insulin sensitizers, such as inositols (due 
to lack of benefit) or thiazolidinediones (due to safety 
concerns), for the treatment of PCOS. In the present study 
only 0.81% patients had been prescribed statins which is in 
accordance with the guidelines that suggest against the use 
of statins for treatment of hyperandrogenism and 
anovulation in PCOS unless additional studies demonstrate a 
favorable risk-benefit ratio. However guidelines suggest 
statins in women with PCOS who meet current indications 
for statin therapy. In the present study out of 123 patients 
1(0.81%) patient had anti-estrogen Clomiphene citrate 
prescribed for PCOS which is in accordance with the existing 
guidelines that recommend Clomiphene citrate (or 
comparable estrogen modulators such as Letrozole) as the 
first-line treatment for anovulatory infertility in women with 
PCOS. In the present study 30.08% had been prescribed anti-
androgen Spironolactone as 91.86% patients had mild 
hirsutism and 2.43% had moderate to severe hirsutism. In 
this study OCPs were prescribed among 46.34% patients. 
The choice of OCPs prescribed to study patients showed that 
only 11(19.29%) patients were prescribed E.E+Cyproterone 
acetate which is in contrast to the study conducted by 
Falsetti et al., in 2001 in which 140 patients were prescribed 
E.E+cyproterone combination11. Similarly studies by 
Mastorakos et al., in 2002 showed that 14 patients were 
given E.E+cyproterone combination12. Thus present study 
shows that Ethinylestradiol and cyproterone acetate 
combination has not been widely used in PCOS patients. In  
this study 29(50.87%) patients were prescribed 
ethinylestradiol (E.E)+Drospirenone whereas the study by 
Guido et al 2004 reported that E.E+ Dospirenone was 
prescribed to 15 patients. Thus, present study revealed that 
E.E+Drospirenone combination has been prescribed 
frequently in PCOS patients, whereas among other OCPs, 
24.56% patients were prescribed  E.E+Norgestal 
combination followed by E.E+Desogestral in 5.26% patients. 
In the present study ethinylestradiol and anti-androgen 
progestins have been prescribed more. A recent 
uncontrolled pilot study on 15 PCOS patients reported that 
treatment with ethinylestradiol (30μg) and Drospirenone 
(3mg) combination resulted in decrease in androgen levels 
after 3 months and improvement in hirsutism after 6 
months13. 
Patient compliance to the medications is one of the most 
important factors which affect the course and prognosis of 
the disease. High adherence 50(40.65%)  in the present 
study may be mainly due to the fact that most PCOS women 
feel distressed about the symptoms like hirsutism and acne. 
Medium 41(33.33%)  and  poor  adherence 32(26.01%) to 
their medications ,which upon counselling was observed 
that most common reason for the patients’ non-adherence to 
prescribed medications was drug intolerance (65.5%) to the 
medications and was mainly observed in patients taking 
Metformin. Similarly Ali and Fonseca in 2012 reported poor 
compliance to Metformin due to multiple daily dosing and 
frequent gastro-intestinal side effects14. Anti-androgen 
Spironolactone is considered safe at lower doses however at 
higher doses when used alone it causes irregular menstrual 
cycles. In the present study 18.9% patients had irregular 
cycles with Spironolactone. Similar reports by Hagag et al., in 
2014 showed that Spironolactone when used alone causes 
irregular periods in up to 80% of women15. 
CONCLUSION 
This study revealed that the nature of drugs prescribed to 
the study population was in consonance with the established 
standard guidelines. In most of the cases OCPs were used as 
a first line treatment and Metformin as the second line 
treatment for PCOS. Most of the women were highly 
adherent to their prescribed medications, which was mainly 
due to the fact that most PCOS women had image issues due 
to hirsutism and others had menstrual disturbance which 
may lead to infertility in later life.  
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